Columns - Pharmaceutical Executive

ADVERTISEMENT

Columns

Opinion: The Media Attacks Ghostwritten Articles

February 1, 2006

Attacking articles in medical journals, those ghostwritten by professional medical writers paid by pharmaceutical companies, is the media's latest attempt to taint anything supported, promoted, or approved by Big Pharma.

Leadership: Wake Up Call

February 1, 2006

Corporate leaders' short-sighted focus on EPS and analyst expectations leaves the US workforce far behind its international counterparts when it comes to cultivating innovation. It's time we stepped up to the plate.

Marketing to Professionals: Streamlined Scheduling

February 1, 2006

Reps say they face restrictions on at least 82 percent of visits to medical offices. Many times these restrictions are arbitrary and disparate, vary by office and region, and are subject to frequent change.

Public Relations: Damage Control

February 1, 2006

Pharma can start rebuilding credibility by developing a thorough, organized campaign that cuts across all disease categories and the industry as a whole.

Washington Report: Cross-Agency Collaboration for Part D

February 1, 2006

While CMS officials praise the CED policy as a way to extend Medicare coverage, patients and industry fear the agency won't reimburse for innovative treatments unless sponsors support post-approval studies.

Global Report: Moving Towards Generic Biologics

February 1, 2006

In Europe, seven of the top-10 injectible drugs are biologics. Generic versions could be priced 25 to 40 percent lower than prescriptions.

Washington Report: PDUFA Blues

January 1, 2006

FDA wants flexibility to use user-fee revenues to extend drug safety oversight, to review direct-to-consumer advertising before it goes public, and to modernize the ever longer and more complex drug development process.

Legal: Shifting Perspective on Off-Label Promotion

January 1, 2006

The omission of criminal charges for off-label promotion of Serostim is surprising, because the government's earlier plea with Pfizer sent a strong signal that it would criminally charge companies engaged in off-label marketing.

Opinion: Memo to von Eschenbach

January 1, 2006

Often, post-approval marketing studies don't materialize because drug companies question their value. Independent review of the need for such studies would address pharma's concern that they may be warranted.

ADVERTISEMENT

Click here